Method of producing microencapsulated form of therapeutic peptide for oral application

FIELD: pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to a method of producing a microencapsulated form of therapeutic peptide for oral application. Method involves administering undecapeptide U2 into lycopodium spores shells (LS) and further formation of alginate microcapsules (AMC) containing the said shell with peptide U2, for suppressing peptidase activity in the intestinal medium the system includes peptidases inhibitor - ovomucoid (OM), which is added to the alginate solution before the stage of forming AMC by ionotropic cross-linking, dispersion of LS with peptide U2 in water solution of sodium alginate and OM was injected in droplets into a settling bath containing an aqueous solution of CaCl2, then filtered, washed with water and dried under certain conditions, dimensions of the AMC make 800-900 mcm, inclusions of U2 and OM therein make 20-30 mcg/ml and 10-20 mcg/mg, respectively.

EFFECT: described method enables to obtain microencapsulated forms of therapeutic peptide for oral application in the form of two-level microcapsules having resistance to gastric acid medium and with prolonged release into the alkaline medium of the intestine.

1 cl, 1 dwg, 1 ex

 



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, particularly a drug preparation for preventing the development of cardiovascular diseases in individuals of a high-risk group. A capsule for preventing the development of cardiovascular diseases in individuals of a high-risk group which contains acetylsalicylic acid tablets coated by partially hydrolised polyvinyl alcohol (PVA), tablets of simvastatin and pravastatin coated by hydroxypropyl methylcellulose (HPMC) and tablets of lisinopril, ramipril or perindopril coated by partially hydrolised polyvinyl chloride. Using the capsule in producing the drug preparation for preventing the development of cardiovascular diseases in individuals of a high-risk group.

EFFECT: capsule is stable at variable temperature and relative humidity, as well as resistant to decomposition of the active ingredients under exposure to light.

8 cl, 29 tbl, 9 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry and represents pharmaceutical composition of prolonged action which includes non-agglomerated particles, containing active substance glycine and auxiliary substances, characterised by the fact that non-agglomerated particles represent nanoparticles with size from 170 to 500 nm, containing biodegradable polymer, as auxiliary substance polyvinyl alcohol as SAS, poloxamer as stabilising agent and cryoprotectant.

EFFECT: invention ensures increase of bioavailability of active substance glycine resulting from application in composition of biodegradable polymer, due to which coefficient of transmission and glycine assimilability increase, and time of glycine activity in organism grows.

4 cl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry and medicine. Method includes: formation of hollow capsules, their hardening and following packing, which differs in the act that as material for manufacturing of capsules applied are substances, able to dissolve in gastric juice with speed, depending on its acidity degree, and manufacturing of capsules is carried out in chamber with increased gas atmosphere pressure. Packing of capsules can also be carried out in chamber with increased pressure, it is necessary to do packing of capsule able to preserve said pressure and provide air-tightness during fixed term of capsule storage.

EFFECT: increased efficiency of method of manufacturing capsules for determination of gastric juice acidity.

3 cl, 1 ex

FIELD: medicine.

SUBSTANCE: method of antidementia drug stabilisation, particularly donepezil or its pharmaceutically acceptable salt, includes the addition of high-molecular acidic substance. Besides the present invention offers a pharmaceutical composition containing an antidementia drug and high-molecular base substance, as well as a high-molecular acidic substance to ensure antidementia drug stabilisation. The invention presents a method of manufacturing of the pharmaceutical composition which involves the stages whereat a solution or a suspension containing the high-molecular acidic substance is added to the pre-mixed antidementia drug and high-molecular base substance for the purpose of antidementia drug stabilisation.

EFFECT: preparation of the stabilised antidementia drug.

20 cl, 11 tbl, 1 dwg, 7 ex

FIELD: medicine.

SUBSTANCE: invention discovers improved composition for profile control of active compound release through the digestive tract, including particles, especially granules, containing the active compounds. They are covered with coating material, solution of which depends on pH value, or polymethacrylate material, solution of which, for preference, depends on pH value, the definite thickness, desirable place and speed of the active compound release. In preferable compositions two or more particles, in which particles of each multitude are covered with the coating material, the solution which depends on pH value, or polymethacrylate material, of different thickness in comparison with the particles of each other multitude, are contained in capsules with enterosoluble coating and provide the active substance release in different desirable places of the digestive tract.

EFFECT: provision of active substance release in desirable places of digestive tract.

28 cl, 7 dwg, 9 ex

FIELD: pharmaceutical agents.

SUBSTANCE: invention relates to solid pharmaceutical formulations for peroral administration useful in treatment of mild and moderately severe dementia such as Alzheimer's disease. Claimed formulation contains Rivastigmin or pharmaceutically acceptable salts thereof. Formulation represent gelatin capsule filled with pellet mixture or mixture of magnesium stearate with nonpareils, or matrix tablet.

EFFECT: preparation with controlled prolonged Rivastigmin release and improved tolerance.

3 cl, 5 ex, 15 tbl

FIELD: medicine; medical engineering.

SUBSTANCE: method involves supplying target materials and core materials, carrying out target materials ablation with washed-out particle materials being produced and coating core materials with the washed-out particle materials. The method is applied under pressure of approximately equal to 10 torr or higher. Coating of thickness from one to several nm is applied at atmospheric pressure with pseudo-fluidized particle substance state, achieved by means of pneumatic pseudo-fluidization, being used.

EFFECT: improved pharmacokinetic drug properties.

22 cl, 22 dwg

The invention relates to medicine and relates to tablets with intersolubility coating and method of its preparation
Hypotensive means // 2554815

FIELD: medicine.

SUBSTANCE: invention represents a hypotensive means, which contains felodipinum as an active component, as well as target additional components: mesoporous silicon dioxide, lactose, hypromeloza. Realisation of the invention ensures the high technological efficiency of the claimed medical means production with the provision of a prolonged release of an active substance with the application of available components. Felodipinum is included into spherical particles with a highly developed mesoporous structure of silicon oxide.

EFFECT: increase of stability in storage and protection from unfavorable environmental factors.

4 cl, 4 ex

FIELD: medicine.

SUBSTANCE: this invention aims at pharmaceutical compositions and methods for making these compositions containing a number of controlled-release particles. At least one assembly of said particles comprises a nucleus containing weakly basic drug substance, an alkaline buffer layer above the nucleus, and a controlled-release coating. The weakly basic drug substance contains at least one nitrogen-containing fragment with pKa from approximately 5 to approximately 14, with a solubility from at least 200 mg/ml at room temperature in an aqueous solution at pH approximately pH 1.2-6.8 and solubility of no more than approximately 10 mg/ml at pH 8 and more. The controlled-release coating contains a water-insoluble polymer. The pharmaceutical composition also contains rapidly degrading microgranules. This invention also aims at pharmaceutical dosage forms containing orally degrading tablets, classical tablets and capsules, as well as methods for making them.

EFFECT: invention provides the sustained release of the weakly basic drug substance in the small intestine.

65 cl, 1 dwg, 1 tbl, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to producing drug preparations, namely represents a process of producing microcapsules of the antiseptic Dorogov's stimulator (ADS fraction 2). The process of microencapsulation represents a method of a non-solvent addition; a microcapsule coating is kappa-carageenan, while a core is the ADS fraction 2.

EFFECT: implementing the invention provides simplifying and accelerating the process of microencapsulation, reduces the microencapsulation loss (higher weight yield).

1 dwg, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of invention refers to medicine, namely to oncology, and can be used in treating cancer in a patient. The method involves administering at least one encapsulated chemotherapeutic agent, and at least one amphiphilic block copolymer in this patient. What is also presented is a composition, a kit for treating cancer in the patient and using the amphiphilic block copolymer.

EFFECT: group of inventions provides potentiating the encapsulated chemotherapeutic agent by stimulating the active chemotherapeutic agent release from liposomes by the use of the amphiphilic block copolymer, which is poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) triblock copolymer, in the composition.

10 cl, 11 dwg, 3 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry, namely represents a method for ensuring a uniform dissolution profile of a pharmaceutical composition of cyclobenzaprine containing inert coated particles with the cyclobenzaprine containing composition of a drug layering for forming IR granules to be coated with a prolonged-release coating for forming ER granules.

EFFECT: developing the method for ensuring the uniform dissolution profile of the pharmaceutical composition.

53 cl, 6 ex, 5 dwg, 4 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to field of microcapsulation of heterocyclic compounds of triazine series, applied in pharmaceutical industry and agriculture as pesticides. Method of obtaining microcapsules includes physical-chemical method of precipitation with non-solvent with application of polyvinyl alcohol as microcapsule envelope. Carbinol and acetone are used as non-solvent. Preparation E 472c is used as emulsifier.

EFFECT: application of invention simplifies the process of obtaining microcapsules, increase of preparation output by weight.

3 ex

FIELD: chemistry.

SUBSTANCE: invention provides a method of encapsulating antiseptic-stimulator Dorogova (ASD) fraction 2. The method is a physical-chemical non-solvent deposition method. When carrying out the method, the cladding of the microcapsules used is sodium alginate and the precipitation agent is carbon tetrachloride.

EFFECT: simple and faster process of producing microcapsules and higher mass output.

2 ex

FIELD: chemistry.

SUBSTANCE: method of encapsulating creatine is a physical-chemical non-solvent deposition method. The envelope used is sodium alginate, which is deposited from a solution in butanol in the presence of a glycerol ester with one or two molecules of edible fatty acids and one or two molecules of citric acid by adding chloroform as a precipitant.

EFFECT: simple and faster process of producing microcapsules and higher mass output.

3 dwg, 3 ex

FIELD: chemistry.

SUBSTANCE: distinctive feature of the present method is the use of betaine as an antioxidant and sodium alginate as a microcapsule envelope, as well as the use of tetrachloromethane as a precipitant when producing microcapsules using a physical-chemical non-solvent deposition method.

EFFECT: simple and faster process of producing microcapsules and higher mass output.

2 ex

FIELD: chemistry.

SUBSTANCE: described is method of obtaining particles of encapsulated with fat-soluble polymer envelope flavour enhancer, which possess supramolecular properties, with fat-soluble polymer being used as microcapsule envelope and flavour enhancer "gooseberry" being used as core in production of encapsulated particles by method of precipitation with non-solvent with application of acetone and butanol as precipitators.

EFFECT: simplification and acceleration of the process of producing microcapsules, reduction of loss in production of microcapsules.

1 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of biotechnology and deals with method of separating mixture of DNA and proteins from epimastigote forms of strain TPAP/MX/2002/Albarrada of Trypanosoma cruzi culture. Characterised method includes obtaining biomass of said strain culture, with further washing of obtained biomass, its concentration to content of not less than 6×108 cells in 1 ml, introduction of synthetic preparation of human defensin α-1 with molecular weight 3.4 kDa into obtained concentrated biomass in amount 20 mcg/ml to its final concentration 3.97 mcM and exposure until pores are formed in lipid membranes. After that obtained suspension is shaken by shaker with further exposure at room temperature for not less than 24 hours, with the following centrifuging obtained medium with separation of mixture of DNA and proteins in liquid phase.

EFFECT: invention makes it possible to obtain product with reduced content of protein components and can be used in further obtaining of preparations.

2 cl, 2 ex

Up!